Naurex: Funding, Investors & Team (Oct 2026)
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.
Naurex has raised $38.0M across 1 funding round on record, the most recent a Series B of $38.0M announced in May 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Naurex Company Profile and Key Stats
Latest funding round on record: May 2022.
Naurex Funding Rounds
Naurex Founders and Leadership Team
No contact details are on record for this team yet.
Naurex Funding Compared to Other Biotechnology Startups
Naurex's latest round of $38.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Naurex in Biotechnology and Evanston
Companies Similar to Naurex
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Naurex Funding FAQs
What does Naurex do?
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.
How much funding has Naurex raised?
Naurex has raised $38.0M across 1 round on record. The most recent is a Series B of $38.0M announced in May 2022.
When did Naurex last raise funding?
Naurex's most recent funding round on record is a Series B of $38.0M, announced in May 2022.
Who founded Naurex?
FundedIQ lists Joseph Moskal (Founder) at Naurex.
Where is Naurex headquartered?
Naurex is based in Evanston, Illinois, United States.
How many employees does Naurex have?
Naurex is in the 11-50 employee band.
How does Naurex's funding compare to other Biotechnology startups?
Naurex's latest round of $38.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Naurex Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Naurex is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.